Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,224 | 187 | 91.6% |
| Education | $294.97 | 3 | 8.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $937.03 | 53 | $0 (2024) |
| Janssen Biotech, Inc. | $412.81 | 11 | $0 (2023) |
| Allergan, Inc. | $349.38 | 39 | $0 (2022) |
| Galderma Laboratories, L.P. | $296.48 | 18 | $0 (2022) |
| GENZYME CORPORATION | $260.13 | 12 | $0 (2022) |
| PFIZER INC. | $228.88 | 16 | $0 (2023) |
| Lilly USA, LLC | $187.76 | 6 | $0 (2023) |
| Celgene Corporation | $163.13 | 4 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $159.45 | 5 | $0 (2023) |
| UCB, Inc. | $129.94 | 6 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32.35 | 2 | ABBVIE INC. ($32.35) |
| 2023 | $392.31 | 13 | Janssen Biotech, Inc. ($213.11) |
| 2022 | $993.59 | 60 | ABBVIE INC. ($384.80) |
| 2021 | $559.17 | 32 | AbbVie Inc. ($229.90) |
| 2020 | $365.52 | 18 | AbbVie Inc. ($171.68) |
| 2019 | $399.28 | 28 | Allergan Inc. ($124.21) |
| 2018 | $230.30 | 14 | Galderma Laboratories, L.P. ($126.23) |
| 2017 | $546.55 | 23 | Celgene Corporation ($139.53) |
All Payment Transactions
190 individual payment records from CMS Open Payments — Page 2 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/07/2022 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $15.91 | General |
| Category: IMMUNOLOGY | ||||||
| 09/26/2022 | Allergan, Inc. | — | Food and Beverage | In-kind items and services | $21.43 | General |
| 09/21/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $22.87 | General |
| Category: IMMUNOLOGY | ||||||
| 09/21/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $1.12 | General |
| Category: IMMUNOLOGY | ||||||
| 09/09/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $12.71 | General |
| Category: IMMUNOLOGY | ||||||
| 09/09/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $5.40 | General |
| Category: IMMUNOLOGY | ||||||
| 09/08/2022 | Lilly USA, LLC | TALTZ (Drug), OLUMIANT | Food and Beverage | In-kind items and services | $20.72 | General |
| Category: Immunology | ||||||
| 08/23/2022 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $15.12 | General |
| 08/22/2022 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: FACIAL AESTHETICS | ||||||
| 08/18/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.28 | General |
| Category: IMMUNOLOGY | ||||||
| 08/01/2022 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $99.99 | General |
| Category: Immunology | ||||||
| 07/26/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $27.90 | General |
| Category: IMMUNOLOGY | ||||||
| 07/25/2022 | Exeltis, USA Inc. | ApexiCon E (Drug) | Food and Beverage | In-kind items and services | $21.75 | General |
| Category: Treatment of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | ||||||
| 07/19/2022 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: Immunology | ||||||
| 07/12/2022 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: Immunology | ||||||
| 07/12/2022 | PFIZER INC. | CIBINQO (Drug) | Food and Beverage | In-kind items and services | $7.50 | General |
| Category: Inflammation & Immunology | ||||||
| 07/07/2022 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $26.09 | General |
| Category: Inflammation | ||||||
| 07/06/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $8.32 | General |
| Category: IMMUNOLOGY | ||||||
| 07/06/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $3.91 | General |
| Category: IMMUNOLOGY | ||||||
| 06/23/2022 | PFIZER INC. | CIBINQO (Drug) | Food and Beverage | In-kind items and services | $42.25 | General |
| Category: Inflammation & Immunology | ||||||
| 06/23/2022 | PFIZER INC. | CIBINQO (Drug) | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: Inflammation & Immunology | ||||||
| 06/23/2022 | ABBVIE INC. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: IMMUNOLOGY | ||||||
| 06/23/2022 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $7.60 | General |
| Category: FACIAL AESTHETICS | ||||||
| 06/23/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $4.98 | General |
| Category: IMMUNOLOGY | ||||||
| 06/13/2022 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $9.59 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 390 | 498 | $50,875 | $20,566 |
| 2022 | 12 | 707 | 1,098 | $111,610 | $47,709 |
| 2021 | 19 | 822 | 1,366 | $196,230 | $88,798 |
| 2020 | 19 | 962 | 1,435 | $233,680 | $106,052 |
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 86 | 95 | $10,925 | $5,220 | 47.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 60 | 61 | $10,675 | $3,815 | 35.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 42 | 44 | $6,600 | $3,603 | 54.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 61 | 68 | $7,480 | $2,422 | 32.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 53 | 60 | $3,600 | $1,974 | 54.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 26 | 27 | $4,725 | $1,588 | 33.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 15 | 15 | $2,250 | $879.36 | 39.1% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 12 | 12 | $1,140 | $536.70 | 47.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 35 | 116 | $3,480 | $528.29 | 15.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 99 | 118 | $17,700 | $10,418 | 58.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 132 | 171 | $19,665 | $9,675 | 49.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 95 | 108 | $18,900 | $7,971 | 42.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 110 | 138 | $15,180 | $4,530 | 29.8% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2022 | 19 | 20 | $9,000 | $4,333 | 48.1% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 51 | 59 | $10,325 | $3,616 | 35.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 37 | 37 | $5,550 | $2,972 | 53.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 37 | 37 | $2,220 | $1,390 | 62.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 77 | 293 | $8,790 | $1,352 | 15.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 14 | 19 | $1,425 | $734.85 | 51.6% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2022 | 18 | 25 | $2,125 | $671.64 | 31.6% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 18 | 73 | $730.00 | $44.58 | 6.1% |
| 17108 | Destruction of skin growth (over 50.0 sq centimeters) | Office | 2021 | 13 | 55 | $41,250 | $25,990 | 63.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 147 | 196 | $22,540 | $12,370 | 54.9% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 95 | 118 | $20,650 | $8,494 | 41.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 73 | 87 | $13,050 | $7,314 | 56.0% |
About Dr. Robert Benson, M.D
Dr. Robert Benson, M.D is a Dermatology healthcare provider based in Ponchatoula, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1962406843.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Benson, M.D has received a total of $3,519 in payments from pharmaceutical and medical device companies, with $32.35 received in 2024. These payments were reported across 190 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($3,224).
As a Medicare-enrolled provider, Benson has provided services to 2,881 Medicare beneficiaries, totaling 4,397 services with total Medicare billing of $263,126. Data is available for 4 years (20